|Articles|August 1, 2003

Experts show wide range of opinion on PCa prevention trial

Seattle-Leading U.S. prostate cancer thought leaders are expressingwidely divergent opinions on the recent announcement of a 25% reductionin prostate cancer incidence in men treated with finasteride (Proscar),according to interviews conducted by Urology Times. Whereas some expertssee the finding as the beginning of a new era in prostate cancer prevention,others say that more data are needed before urologists can confidently applythe finding to clinical practice.

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related to this article

October 13th, 2026

Butterfly Prostatic Retraction Device granted EU MDR certification for BPH

Butterfly Medical has also submitted a premarket approval application to the FDA.

October 13th, 2026

Matching mCSPC treatment to the patient, not just the trial data

Moderators and participants reviewed ARANOTE, ARACOG, and ARASEC data and how they inform individualized treatment for mCSPC.

October 13th, 2026

Timothy Clinton, MD, reviews bladder cancer data from 2026 AUA Northeastern Section Meeting

Timothy N. Clinton, MD, recaps bladder cancer data from the 2026 AUA Northeastern Section meeting, including BOND-003 cretostimogene results and safety data on mitomycin intravesical solution.

October 12th, 2026

When surgery may be needed for prolonged ischemic priapism

Juan J. Andino, MD, MBA, discusses surgical decision-making in prolonged ischemic priapism and how ischemia duration affects erectile dysfunction risk and treatment timing.

October 12th, 2026

Study compares PSMA-PET radiopharmaceuticals in prostate cancer recurrence

Jack R. Andrews, MD, discusses BED-PSMA-411 findings comparing PSMA-PET detection rates and urinary excretion in prostate cancer biochemical recurrence.